Serum GDF9 and BMP15 as potential markers of ovarian function in women with and without polycystic ovary syndrome.

Autor: Riepsamen AH; Fertility & Research Centre, School of Clinical Medicine, University of New South Wales Sydney, New South Wales, Sydney, Australia., Donoghoe MW; Stats Central, Mark Wainwright Analytical Centre, University of New South Wales Sydney, Sydney, New South Wales, Australia., Indran IR; Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Hechtman L; Fertility & Research Centre, School of Clinical Medicine, University of New South Wales Sydney, New South Wales, Sydney, Australia., Robertson DM; Fertility & Research Centre, School of Clinical Medicine, University of New South Wales Sydney, New South Wales, Sydney, Australia., Gilchrist RB; Fertility & Research Centre, School of Clinical Medicine, University of New South Wales Sydney, New South Wales, Sydney, Australia., Ledger WL; Fertility & Research Centre, School of Clinical Medicine, University of New South Wales Sydney, New South Wales, Sydney, Australia., Yong EL; Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Jazyk: angličtina
Zdroj: Clinical endocrinology [Clin Endocrinol (Oxf)] 2023 Apr; Vol. 98 (4), pp. 567-577. Date of Electronic Publication: 2022 Dec 18.
DOI: 10.1111/cen.14851
Abstrakt: Objective: Growth differentiation factor-9 (GDF9) and bone morphogenetic protein-15 (BMP15) are critical paracrine regulators of female fertility and are predominantly expressed by oocytes. However, it is unknown if serum concentrations reflect changes in ovarian function and/or reproductive endocrine disorders. This study aimed to determine if serum GDF9/BMP15 are associated with ovarian, pituitary, oestrogenic, androgenic and metabolic characteristics and the ovarian pathologies, polycystic ovarian morphology (PCOM) and polycystic ovary syndrome (PCOS).
Design: Women aged 21-45 years (n = 381) were included from a cross-sectional study at the National University Hospital, Singapore.
Patients: Participants were volunteers and patients with possible PCOS.
Measurements: Anthropometric measurements, transvaginal ultrasound scans and serum sampling were performed and a questionnairecompleted. Serum GDF9 and BMP15 concentrations were matched with menstrual cycle length, ovarian protein and steroid hormone production, pituitary hormone production and metabolic assessments in women with PCOM or PCOS and those with neither (control).
Results: Serum GDF9 and BMP15 were detectable in 40% and 41% of women, respectively and were positively correlated with each other (r = 0.08, p = 0.003). GDF9, but not BMP15, was positively correlated with ovarian volume (p = 0.02) and antral follicle count (AFC) (p = 0.004), but not with anti-Müllerian hormone (p = 0.05). However, serum GDF9 and BMP15 concentrations were not significantly different between control, PCOM and PCOS women, nor associated with androgenic or metabolic PCOS features. However, the relationship between GDF9 and AFC differed between control, PCOM and PCOS women (p = 0.02).
Conclusions: Serum GDF9 and BMP15 concentrations somewhat reflect ovarian but not androgenic or metabolic characteristics of PCOS, with increased GDF9 reflecting high AFC as seen in PCOM/PCOS.
(© 2022 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: